Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2)

drug protocol number
C0371002
drug sponsor
Pfizer
drug study
PF-06838435
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase